Cargando…

Retinal Pigment Epithelial Cells Express a Functional Receptor for Glucagon-Like Peptide-1 (GLP-1)

Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that has been shown to improve glucose homeostasis in type 2 diabetes. The biological effects of GLP-1 are mediated by its specific receptor GLP-1R that is expressed in a wide range of tissues, where it is responsible of the extra-pan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puddu, Alessandra, Sanguineti, Roberta, Montecucco, Fabrizio, Viviani, Giorgio L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836565/ https://www.ncbi.nlm.nih.gov/pubmed/24307763 http://dx.doi.org/10.1155/2013/975032

Ejemplares similares

Glucagon-Like Peptide-1 Secreting Cell Function as well as Production of Inflammatory Reactive Oxygen Species Is Differently Regulated by Glycated Serum and High Levels of Glucose
por: Puddu, Alessandra, et al.
Publicado: (2014)

Glucagon-Like Peptide-1 Triggers Protective Pathways in Pancreatic Beta-Cells Exposed to Glycated Serum
por: Puddu, Alessandra, et al.
Publicado: (2013)

An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes
por: Puddu, Alessandra, et al.
Publicado: (2013)

Evidence for the Gut Microbiota Short-Chain Fatty Acids as Key Pathophysiological Molecules Improving Diabetes
por: Puddu, Alessandra, et al.
Publicado: (2014)

Effects of High Glucose Levels and Glycated Serum on GIP Responsiveness in the Pancreatic Beta Cell Line HIT-T15
por: Puddu, Alessandra, et al.
Publicado: (2015)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Advanced Glycation End Products Play Adverse Proinflammatory Activities in Osteoporosis
por: Sanguineti, Roberta, et al.
Publicado: (2014)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Update on the Protective Molecular Pathways Improving Pancreatic Beta-Cell Dysfunction
por: Puddu, Alessandra, et al.
Publicado: (2013)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
por: Unger, Jeffrey R., et al.
Publicado: (2011)

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021)

Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
por: Tanday, Neil, et al.
Publicado: (2021)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis
por: Jin, Yue, et al.
Publicado: (2015)

Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
por: Ang, Richard, et al.
Publicado: (2018)

Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: Involvement of Oxidative Stress
por: Ramos, Hugo, et al.
Publicado: (2020)

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
por: Geloneze, Bruno, et al.
Publicado: (2017)

Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning
por: Basalay, Marina V., et al.
Publicado: (2016)

Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
por: Diz-Chaves, Yolanda, et al.
Publicado: (2020)

Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals
por: Model, Jorge F A, et al.
Publicado: (2022)

DNA methylation of the glucagon-like peptide 1 receptor (GLP1R) in human pancreatic islets
por: Hall, Elin, et al.
Publicado: (2013)

Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain
por: Farkas, Erzsébet, et al.
Publicado: (2020)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
por: Xu, Dan, et al.
Publicado: (2022)

Ultrastructural Study on Colocalization of Glucagon-Like Peptide (GLP)-1 with GLP-2 in Chicken Intestinal L-Cells
por: NISHIMURA, Kei, et al.
Publicado: (2013)

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection()()
por: Ussher, John R., et al.
Publicado: (2014)

In Vitro and In Vivo Effects of Natural Putative Secretagogues of Glucagon-Like Peptide-1 (GLP-1)
por: Rafferty, Eamon P., et al.
Publicado: (2011)

Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
por: Basalay, Maryna V., et al.
Publicado: (2020)

Regulation of Human Sortilin Alternative Splicing by Glucagon-like Peptide-1 (GLP1) in Adipocytes
por: Lui, Ashley, et al.
Publicado: (2023)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients
por: Huang, Jingwen, et al.
Publicado: (2018)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
por: Cheng, Dihe, et al.
Publicado: (2022)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain
por: Bae, Choon Sang, et al.
Publicado: (2017)

Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications
por: Manandhar, Bikash, et al.
Publicado: (2014)

The Antidiabetic Mechanisms of Polyphenols Related to Increased Glucagon-Like Peptide-1 (GLP1) and Insulin Signaling
por: Domínguez Avila, J. Abraham, et al.
Publicado: (2017)

Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics
por: Kabahizi, Anita, et al.
Publicado: (2021)

Genetic Evidence for Repurposing of GLP1R (Glucagon‐Like Peptide‐1 Receptor) Agonists to Prevent Heart Failure
por: Daghlas, Iyas, et al.
Publicado: (2021)

Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
por: Bulum, Tomislav
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p8knhfa0dot51u8loo1a3lo24c